175 Longitudinal change in biomarkers 15. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligandreceptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4):279-87. 16. Verfaillie SCJ, Golla SSV, Timmers T, Tuncel H, van der Weijden CWJ, Schober P, et al. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study. Journal of Cerebral Blood Flow & Metabolism. 2020:0271678X20915403. 17. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378-84. 18. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, et al. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience. 2017;9:117. 19. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-6. 20. Oh M, Seo M, Oh SY, Kim H, Choi BW, Oh JS, et al. Clinical significance of visually equivocal amyloid PET findings from the Alzheimer’s Disease Neuroimaging Initiative cohort. Neuroreport. 2018;29(7):553-8. 21. Okada Y, Kato T, Iwata K, Kimura Y, Nakamura A, Hattori H, et al. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study. Ann Nucl Med. 2020;34(2):108-18. 22. Bischof GN, Bartenstein P, Barthel H, van Berckel B, Doré V, van Eimeren T, et al. Toward a Universal Readout for (18)F-Labeled Amyloid Tracers: The CAPTAINs Study. J Nucl Med. 2021;62(7):999-1005. 23. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron. 2008;60(4):534-42. 24. Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected nonAlzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. The Lancet Neurology. 2016;15(10):1044-53. 25. Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM, Alzheimer’s Disease Neuroimaging I. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020;95(15):e2075-e85. 26. Koychev I, Vaci N, Bilgel M, An Y, Muniz GT, Wong DF, et al. Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals. Alzheimers Dement (Amst). 2020;12(1):e12019. 27. Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, et al. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. J Alzheimers Dis. 2019;69(3):783-93. 7